Company intelligence / Profile preview

Cellex Incorporated

Morrisville, North Carolina, United Statescellex.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Cellex has developed over 50 pioneering diagnostic tests across multiple platforms. During the COVID‑19 pandemic, it rapidly brought several commercial tests to market. Its SUSPENCE® bioreactor technology claims up to 10x higher cellular production efficiency than competitors and significant cost reductions in vaccine manufacturing simulations[5][1].

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Diagnostic assays (immunoassays, molecular diagnostics)Instruments for disease testing[1][2][6]
Industry: Molecular Diagnostics

Drug pipeline

4 assets

UniCAR-T-CD123

Phase 1

Indications: Hematological malignancies

3 more assets in the full pipeline.

Partnerships

Exclusive manufacturing partner in Zhengzhou, Hunan Province, China; no major pharma partnerships publicly disclosed as of now[1].

Beyond the preview

Go deeper on Cellex Incorporated.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellex Incorporated.